Compare SRPT & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRPT | OGN |
|---|---|---|
| Founded | 1980 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 1.7B |
| IPO Year | 2000 | 2020 |
| Metric | SRPT | OGN |
|---|---|---|
| Price | $16.66 | $6.34 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 28 | 4 |
| Target Price | ★ $25.76 | $11.75 |
| AVG Volume (30 Days) | 2.1M | ★ 3.2M |
| Earning Date | 06-01-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 1.26% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.72 |
| Revenue | $2,198,237,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | N/A | $0.42 |
| Revenue Next Year | N/A | $1.67 |
| P/E Ratio | ★ N/A | $8.83 |
| Revenue Growth | ★ 15.58 | N/A |
| 52 Week Low | $10.42 | $6.18 |
| 52 Week High | $81.87 | $15.88 |
| Indicator | SRPT | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 40.94 | 30.98 |
| Support Level | $15.51 | $6.18 |
| Resistance Level | $19.55 | $7.87 |
| Average True Range (ATR) | 0.87 | 0.25 |
| MACD | 0.09 | -0.05 |
| Stochastic Oscillator | 30.34 | 7.24 |
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.